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The pharmacokinetics of grepafloxacin were determined in albino and pigmented rabbits
following a single 10 mg/kg intravenous administration. The penetration of grepafloxacin into
various ocular tissues was also determined after continuous intravenous infusion in both types
of animal. Grepafloxacin showed a bicompartmental model of distribution in both pigmented
and albino rabbits with significant differences in the pharmacokinetics between the two types of
animal. After continuous intravenous infusion, significantly greater penetration of grepa-
floxacin was found in the iris, cornea and chorioretina of pigmented rabbits compared with
albino rabbits.
Introduction
Fluoroquinolones are important therapeutic agents for the
treatment of bacterial ocular infections,1–3 with good bacteri-
cidal activity against many of the Gram-negative aerobes, as
well as limited activity against the Gram-positive bacteria that
cause these infections.4–8 Moreover, they show excellent
pharmacokinetic properties, such as long half-life, good
tissue distribution, low protein binding, high antimicrobial
activity and relatively few side-effects. The newer fluoro-
quinolones show good penetration into ocular tissues but with
a spectrum of activity that includes coagulase-negative
staphylococci.9
Fluoroquinolones have been found to be important thera-
peutic agents for the treatment of ocular infections, such as
keratitis or conjunctivitis, when given by topical administra-
tion.1,7,10 However, only a few authors have reported the
systemic use of fluoroquinolones in ocular infections. Keren
et al.11 studied the ocular penetration of ciprofloxacin into
both the vitreous and aqueous humour. Virgil-Alfaro et al.12
studied the ocular penetration of ciprofloxacin in pigs and
reported the treatment of experimental endophthalmitis in
rabbits with various fluoroquinolones. Gatti & Panozzo13 and
Ng et al.,14 using experimental models of endophthalmitis in
rabbits, studied the ocular penetration of trovafloxacin and
ofloxacin. Hatano et al.15 compared the ocular penetration of
lomefloxacin with that of other antimicrobial agents such as
sulbenicillin and gentamicin, and finally, Cochereau-Massin
et al.1,7,8 and Liu et al.16 compared the ocular penetration of
various fluoroquinolones with that of imipenem, vancomycin
and amikacin.
Grepafloxacin, although not currently marketed, exhibits
good activity against many of the potential pathogens that
may cause ocular infections.10,17–20
The aim of this study was therefore to evaluate the pharma-
cokinetics of grepafloxacin in albino and pigmented rabbits
following intravenous administration, and establish whether
there were differences between the pharmacokinetics or
ocular penetration in these two types of animal.
Materials and methods
Animals were obtained and cared for in accordance with the
recommendations of the European Community guidelines for
the use of experimental animals.
Chemicals
Grepafloxacin was kindly supplied by Otsuka Pharmaceut-
ical (Barcelona, Spain). Other chemicals were obtained from
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various commercial sources. All reagents were of HPLC
grade.
Animal housing
Ten New Zealand rabbits (albino) and 10 Gigante de España
rabbits (pigmented) weighing 3.5–4 kg were obtained from
the Animal Experimentation Service of the University of
Zaragoza. They were housed in rooms with a controlled tem-
perature (20°C) and light cycle (12/12 h). The animals were
maintained on water and standard laboratory chow ad libitum
throughout the study. Each animal was judged to be clinically
normal by physical examination before beginning the experi-
ment. During this procedure, the heart and respiratory rates
and the rectal temperature were also recorded.
Pharmacokinetic studies
Grepafloxacin was administered intravenously (iv) in the
marginal ear vein of five pigmented rabbits and five albino
rabbits as a bolus dose of 10 mg/kg body weight. Serial blood
samples (1 mL) were drawn from a catheter inserted in the
contralateral central ear artery at 0, 5, 10, 15, 30,45, 60, 90,
120, 180, 240 and 360 min into heparinized tubes. The
samples were centrifuged and the plasma stored at –80°C
until analysis.
Intraocular penetration studies
Grepafloxacin was administered in the marginal ear vein of
five pigmented rabbits and five albino rabbits as an iv continu-
ous infusion (4.6 mg/h) using a Mod M312 Gilson infusion
pump (Pacisa, Zaragoza, Spain). Serial blood samples were
drawn from a catheter inserted in the contralateral ear artery.
Blood levels were measured until 200 min, in order to ensure
that steady-state plasma concentrations of grepafloxacin
(expected concentration 1.5 µg/mL) were achieved. The ani-
mals were then killed by iv administration of pentobarbital
(30 mg/kg). Aqueous and vitreous humour samples were
aspirated by puncture with a 23-gauge needle. The eyes were
then removed and stored at –80°C. Frozen eyes were dis-
sected and the ocular tissues, cornea, iris, lens, chorioretina
and sclera, were obtained and stored at –80°C until analysis.
HPLC assay of grepafloxacin
Grepafloxacin was assayed in plasma and ocular tissues
according to an HPLC method described previously.21
Pharmacokinetic analysis
The time course of the grepafloxacin plasma concentration
(C) in both types of rabbit, and after using the Akaike
criterion,22 was described using the following equation:
(Equation 1)
where C1 and λ1 and Cz and λz are, respectively, the compart-
mental kinetic variables of distribution and elimination phases
obtained by non-linear least squares regression analysis,
using a weighting factor of 1/C2. The half-life in the distribu-
tion and elimination phases was calculated as t1/2λ1 = ln 2/λ1
and, t1/2λz = ln 2/λz where λ1 and λz are, respectively, the slope
of the distribution and elimination phases.
Total body clearance was calculated as Clb = Dose/
AUCgrepafloxacin, where AUCgrepafloxacin is the area under the
grepafloxacin blood concentration versus time curve, calcul-
ated by the trapezoidal rule to the last data point (Clast) and
extrapolated to infinity by dividing Clast by the slope of the
elimination phase. Finally, the volume of distribution of the
central compartment (Vc) and the volume of distribution
under the area (Vd) were calculated as Vc = Dose/Cz and
Vd = Dose/(AUC grepafloxacin × λz).
Statistical evaluation
The pharmacokinetic values obtained in the pigmented and
albino rabbits are presented as mean ± S.D., except for the
half-life, where the harmonic mean is shown. Comparisons
between iv pharmacokinetic parameters from albino and
pigmented rabbits were carried out using Student’s unpaired
t-test. The differences between the respective tissue concen-
trations were obtained by one-way analysis of variance
(ANOVA). In all instances, P < 0.05 was considered to be
statistically significant.
Results
The grepafloxacin plasma concentration–time plot following
bolus injection for the two types of rabbit is shown in Figure 1,
and the mean values for the grepafloxacin pharmacokinetic
parameters are shown in Table 1. In all instances, the best fit
for the pharmacokinetic data was obtained with a two-
compartment model, as determined by the use of the Akaike
criterion.22 Following iv administration, grepafloxacin had a
distribution phase in both albino and pigmented rabbits of
∼40 min. When the pharmacokinetic parameters of both
albino and pigmented rabbits were compared, significant
differences were observed in C1, Cz, λz, Vc, Vd, AUC and Clb
(P < 0.05) (Table 1).
Figure 2 shows the mean plasma levels of grepafloxacin
during continuous iv infusion of grepafloxacin in both albino
and pigmented rabbits. After iv infusion of grepafloxacin, we
found that the steady-state plasma concentrations of this drug
were ∼1.5 mg/L in both albino and pigmented rabbits.
In general, there were differences in the penetration of
grepafloxacin into all ocular tissues, except aqueous humour,
between albino and pigmented rabbits, with these differences
C Cl e λ– lt× Cz e λ– zt×+=
 at Centro de Inform
ación y Docum






Pharmacokinetics and ocular penetration of grepafloxacin
543
reaching statistical significance for the chorioretina, cornea
and iris (Table 2).
Discussion
Drugs used to treat eye infections must have a broad spectrum
of activity and must reach effective concentrations in ocular
tissue, especially in the vitreous and aqueous humours. How-
ever, when administered by the systemic route, many anti-
biotics show poor ocular penetration and the levels reached
are often insufficient to cure virulent endophthalmitis.1 Thus,
new drugs that offer both good ocular penetration by the
systemic route and a broad spectrum of activity against the
potential pathogens in ocular infections are required.
Following iv administration of grepafloxacin the best
pharmacokinetic fit of the plasma concentration was obtained
for a two-compartment open model. To date there are no other
reports on the pharmacokinetics of grepafloxacin in rabbits,
with all the published data for grepafloxacin obtained from
humans or in rats.10,17–20,23–25 Our results are similar to the
findings reported for the pharmacokinetics of other fluoro-
quinolones such as ciprofloxacin, sparfloxacin and enro-
floxacin.5,16,26–29 In our studies, the distribution kinetics of
grepafloxacin were characterized by a large Vd, which agrees
with findings reported in other animal species.5 In our studies,
when the pharmacokinetic parameters were compared
between albino and pigmented rabbits, the latter exhibited
higher values of Vd, Clb and t1/2 than the former. Similar dif-
ferences have also been described by other authors when
the pharmacokinetics of pefloxacin was compared between
albino and pigmented rabbits.1
In this article, we have also studied the penetration of
grepafloxacin into ocular structures after continuous iv infu-
sion of grepafloxacin, to steady-state plasma concentrations.
We found clinically relevant concentrations of grepafloxacin
in all ocular tissues, with the highest concentrations found in
the iris and chorioretina of pigmented rabbits. Cochereau-
Massin et al.1 described a similar result working with pefloxa-
cin, and other authors have demonstrated that penetration
of sparfloxacin or moxifloxacin in the iris and ciliary body is
related to the melanin concentration of these tissues.30–32 A
Figure 1. Mean ± S.D. plasma concentrations of grepafloxcin following
an iv bolus dose of 10 mg/kg grepafloxacin. Filled triangles, pigmented
rabbits; open triangles, albino rabbits.
Table 1. Pharmacokinetic parameters of grepafloxacin in albino and pigmented rabbits 
given a single iv administration of 10 mg/kg body weight
These terms are related to rate constants for the specific two-compartment pharmacokinetic model. C1 and Cz
are the coefficients and λ1 and λz are the the exponents derived by non-linear least squares regression of con-
centration data to equation  . t1/2λ1 = distribution half-life; t1/2λz, elimination half-
life; Vc, volume of the central compartment; Vd, apparent volume of distribution calculated by the area method;
AUC, area under the blood concentration time curve; Clb, body clearance.
aSignificantly different.
bHarmonic mean.
Parameter (units) Albino (mean ± S.D.) Pigmented (mean ± S.D.)
C1a (mg/L) 13.9 ± 1.5 3.0 ± 0.8
λ1 (min) 0.0737 ± 0.0162 0.0591 ± 0.0431
Cza (mg/L) 4.3 ± 1.0 0.5 ± 0.2
λza (min) 0.0098 ± 0.0018 0.0054 ± 0.0028
t1/2λ1 (min) 9b 11b
t1/2λz (min) 71b 126b
Vca (mL/kg) 723.9 ± 82.0 3576.0 ± 969.2
Vda (mL/kg) 2469.5 ± 305.5 2067.7 ± 11350.3
AUCa (µg/mL/min) 615.2 ± 151.1 139.44 ± 19.20
Clba (mL/min.kg) 17.06 ± 4.16 72.74 ± 9.40
C Cl e λ– lt× Cz e λ– zt×+=
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similar influence of ocular pigments has been described for a
number of other drugs, such as mydriatics, aminoglycosides
or other fluoroquinolones.33–35
For all ocular structures, the penetration of grepafloxacin
was found to be higher in pigmented than in albino rabbits.
The degree of penetration was influenced by tissue vascular-
ization, in that vascular tissues, such as the chorioretina and
the iris, showed grepafloxacin ratios > 1, while non-vascular
tissues, such as the aqueous humour, vitreous humour and
lens, showed grepafloxacin ratios < 1 (Table 2). However, in
spite of the fact that the sclera is a non-vascular tissue it
showed ratios > 1. This tissue is very difficult to separate from
the chorioretina and contamination from chorioretina could
explain this concentration finding. This may also explain the
findings of Cochereau-Massin et al.,1 who found high con-
centrations in the sclera when studing the penetration of
pefloxacin into ocular structures.
In conclusion, we have been able to demonstrate that
grepafloxacin, a third-generation fluoroquinolone, has good
capacity to cross the various ocular barriers after systemic
administration, to achieve concentrations above those needed
to inhibit bacteria that cause intraocular infections.
These results confirm the good penetration of fluoro-
quinolones into ocular tissues and highlight potential differ-
ences that may be observed when using pigmented or albino
rabbits.
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